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Abstract Drug combinations can improve angiostatic
cancer treatment efficacy and enable the reduction of side
effects and drug resistance. Combining drugs is non-trivial
due to the high number of possibilities. We applied a
feedback system control (FSC) technique with a popula-
tion-based stochastic search algorithm to navigate through
the large parametric space of nine angiostatic drugs at four
concentrations to identify optimal low-dose drug combi-
nations. This implied an iterative approach of in vitro
testing of endothelial cell viability and algorithm-based
analysis. The optimal synergistic drug combination, con-
taining erlotinib, BEZ-235 and RAPTA-C, was reached in
a small number of iterations. Final drug combinations
showed enhanced endothelial cell specificity and syner-
gistically inhibited proliferation (p \ 0.001), but not
migration of endothelial cells, and forced enhanced num-
bers of endothelial cells to undergo apoptosis (p\ 0.01).
Successful translation of this drug combination was
achieved in two preclinical in vivo tumor models. Tumor
growth was inhibited synergistically and significantly
(p\ 0.05 and p\ 0.01, respectively) using reduced drug
doses as compared to optimal single-drug concentrations.
At the applied conditions, single-drug monotherapies had
no or negligible activity in these models. We suggest that
FSC can be used for rapid identification of effective, re-
duced dose, multi-drug combinations for the treatment of
cancer and other diseases.
Keywords Anti-angiogenesis · Combination therapy ·
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Introduction
Anti-angiogenic therapies are routinely used in the treat-
ment of various cancers [1–3]. Their contribution to the
prolongation of patient survival, however, is often limited
mainly due to disease and patient heterogeneity [4, 5],
toxicity [6], induction of metastasis [7] and drug resistance
[8, 9]. Redundancy of growth factor signaling pathways
makes angiogenesis a robust physiological function [10,
11], where targeting multiple pathways with drug combi-
nations may be necessary for efficient therapy [12].
Although difficult to predict, in such drug combinations
one may encounter synergistic, additive or antagonistic
interactions between drugs. Synergistic interactions can
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lead to effective angiogenesis inhibition at reduced doses
as compared to single-drug therapies. Combination strate-
gies may thus lead to enhanced efficacy [13, 14] with
limited side effects [15] and reduced probability of devel-
oping drug resistance [16, 17].
Combinations of anti-angiogenic drugs have often re-
sulted in significant clinical toxicity [18], even when
designed to target complementary pathways [19]. This is
because drugs to be combined are frequently selected based
on their success as single agents [20] and tend to be used in
combination at their maximum tolerated single agent dos-
es, thus increasing the risk of toxicity and resistance [21].
When trying to identify an optimal combination starting
from, for instance, 10 drugs at 5 doses, one will have to test
nearly 10 million (510) combinations. To overcome this
challenge, we employed a feedback system control (FSC)
technique to rapidly identify the most powerful drug
combinations with minimal experimental effort [22]
(Supplementary Methods). In combination with the dif-
ferential evolution (DE) algorithm [23], an iterative
approach of experimental testing in an endothelial cell
viability assay and mathematical analysis (a process of
selection, where only the permutations which improve the
system’s response are maintained) drove the system to
converge toward an optimal solution, i.e., maximal inhi-
bition of endothelial cell growth. Although others have
tried to optimize drug combinations [24–27], see Supple-
mentary Methods, the advantage of our approach is
that FSC is phenotypically driven, i.e., no mechanistic in-
formation is required in order to rapidly identify
experimentally verifiable optimal drug combinations [22].
The aim of the present study was to find an optimal low-
dose, synergistic anti-angiogenic drug combination using
the FSC technology, and to validate this drug combination
in preclinical tumor models. The FSC technique, together
with a second-order linear regression model to allow for
elimination of less effective drugs, resulted in the identi-
fication of the optimal low-dose combination containing
erlotinib (EGFR inhibitor [28]), RAPTA-C (histone inac-
tivator [29]) and BEZ-235 (a dual PI3K/mTOR inhibitor
[30]). This final drug combination synergistically inhibited
ECRF24 viability, while having minimal effects on non-
endothelial cell types. We successfully translated this
in vitro optimized drug combination to inhibit tumor
growth in two preclinical tumor models.
Materials and methods
Cell viability, migration and apoptosis assay
Cell viability and migration assays were performed as
previously described. Cells were seeded in a 96-well
culture plate at a density of 2.5–10 9 103 cells/well. Cells
were incubated with drugs for 72 h (for drug acquisition
and cells and culture conditions, see Supplementary
Methods). Drugs were premixed in culture medium and
applied at the doses provided in Table 1. Cell viability was
assessed using the CellTiter-Glo luminescence assay
(Promega, Madison, WI, USA). For migration assays,
ECRF24 and 786-O were seeded in 96-well cell culture
plates (3 9 104 cells/well) 24 h prior to making the scratch
(Peira Scientific Instruments, Beerse, Belgium). Drugs
were premixed in culture medium and applied at doses
indicated in Supplementary Fig. S2A. Images were auto-
matically captured on a Leica DMI3000 microscope
(Leica, Rijswijk, Netherlands) at 59 magnification with
Universal Grab 6.3 software (DCILabs, Keerbergen, Bel-
gium). Scratch sizes were determined at t = 0 h and t = 7 h
using Scratch Assay 6.2 (DCILabs), and values reported
represented the absolute closure of the scratch (initially
subtracting the final scratch area). Apoptosis was measured
after drug exposure, trypsinization and incubation with
propidium iodide (PI, 20 µg/ml) in DNA extraction buffer
[31], by flow cytometry. Tip cells were flow cytometrically
quantified by CD34 [32] staining, and morphology was
studied in vivo using the CAM assay [33] (see Supple-
mentary Methods).
The feedback system control (FSC) technique
and data modeling
The FSC technique was employed as previously described
[34, 35]. FSC was implemented using the DE algorithm,
Table 1 Drug dose values used in the in vitro cell viability assays
Dose (μM)
Drug 3 (ED10)
a 2 (ED5)
b 1 (ED0)
c
1. Anginex 1.80d 0.76 0.13
2. Bevacizumab 15.00 10.00 1.00
3. Axitinib 1.00 0.30 0.01
4. Erlotinib 2.00 0.50 0.10
5. Anti-HMGB1 Ab 0.17 0.09 0.02
6. Sunitinib 0.50 0.10 0.05
7. Anti-vimentin Ab 0.26 0.17 0.09
8. RAPTA-C 5.00 1.00 0.05
9. BEZ-235 0.005 0.001 0.0005
a Dose 3, representing ED10, is the dose where 10 % of the maximal
response was observed
b Dose 2, representing ED5, is the dose where 5 % of the maximal
response was observed
c Dose 1, representing ED0, is the dose representing half the maximal
concentration where no effect was observed
d Concentrations throughout the table are in μM
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and two separate optimizations were performed with the
cellular outputs of ECRF24 cell viability (proliferation)
and migration assays. Nineteen drug combinations were
tested per iteration, and 10 iterations were performed in
each optimization until a plateau in the best output value
was reached. For dilutions and culture conditions, see
Supplementary Methods. The cells were incubated in 50 µl
of each combination for 72 h in the viability assay or for
7 h in the migration assay.
Second-order linear regression models were generated
using the data obtained from each optimization. Data were
modeled using real concentration values, and both con-
centration values and cell viability output data were
transformed using the z score function in MATLAB. For
detailed description, see Supplementary Methods.
Human ovarian carcinoma grown on the chicken
chorioallantoic membrane (CAM)
Human ovarian carcinoma tumors were implanted on the
CAM as previously described [36]. On embryo develop-
ment day (EDD) 7, 1 9 106 A2780 carcinoma cells were
prepared as a spheroid in a 25-µl hanging drop and were
transplanted onto the CAM surface 3 h after preparation.
Treatment began 3 days after tumor implantation (EDD10)
when vascularized tumors were visible. Drug combinations
were freshly prepared and administered as a 20-µl intra-
venous injection. Treatment was performed twice, and
tumor growth was monitored and measured daily
(volume = width2 9 length 9 0.52).
Colorectal carcinoma xenograft model
Female Swiss nu/nu mice aged 6–8 weeks were obtained
from Charles River (weight 20–30 g). Mice were
inoculated in the right flank with 100 µl DMEM with 1
million LS174T cells. LS174T cells were obtained from
ECACC, Salisbury, UK (authentication by STR PCR), and
were used within 6 months of resuscitation. Palpable tu-
mors were present within 3–5 days, at which time
treatment was initiated. Mice were treated daily by oral
gavage and i.p. injection as indicated (Table 2) and were
monitored daily for tumor size and body weight (see
Supplementary Methods).
Immunohistochemistry
CD31 staining (SZ31, Dianova, Hamburg, Germany) was
performed using donkey anti-rat biotinylated secondary
antibodies (Jackson, Suffolk, UK) and streptavidin-HRP
(Dako, Glostrup, Denmark) and visualized by 3,3´-di-
aminobenzidine (DAB, see Supplementary Methods).
Statistical analysis
Values are given as mean values ± SD. Statistical analysis
was performed using a two-sided student’s t test and the
two-way ANOVA assay. *p\ 0.05 and **p\ 0.01 were
considered statistically significant.
Results
Selection of drug combinations by the FSC
technique
Nine drugs targeting a broad spectrum of endothelial cell
signaling pathways (Supplementary Fig. S1; Supplemen-
tary Methods) were selected for FSC-based screening
(Fig. 1a): anginex (1), bevacizumab (2), axitinib (3), er-
lotinib (4), anti-HMGB1 Ab (5), sunitinib (6), anti-
vimentin Ab (7), RAPTA-C (8) and BEZ-235 (9). Single-
drug dose–response curves were generated for both cell
viability (example for sunitinib provided, Fig. 1b) and
migration, using in vitro bioassays (Supplementary Fig.
S2A). The optimization was carried out with each com-
pound at four low doses. The highest concentration, dose 3
or ED10, was the dose where 10 % of the maximal response
was observed, dose 2 or ED5, where 5 % of the maximal
response was observed, dose 1 or ED0, represented half the
maximal dose where no effect was observed, and dose 0,
where no drug was present (Table 1). Starting from ran-
domly selected drug combinations (Fig. 1a, yellow arrow),
the FSC technique implements an algorithm-guided closed-
loop feedback search to iteratively optimize the results of
an in vitro cell assay (blue arrows). The box plot in Fig. 1c
provides the median and interquartile ranges of the output
results of the drug combinations identified by the end of
each iterative cycle of the FSC optimization. After 10 it-
erations of 19 drug mixtures, the optimization goal was
reached, i.e., no further improvement of the lowest output
efficacy could be achieved, indicating that the maximum
activity (approx. 70 % inhibition) had been reached.
The data obtained from this optimization process were
used to build a second-order stepwise linear regression
model [37] (Supplementary Methods) to determine the
relative importance of the individual drugs. This model
generated regression coefficients (Fig. 1d) corresponding to
single-drug linear effects (left panel), two-drug pair-wise
interaction effects (middle panel) and single-drug quadratic
effects (right panel). Compounds with the largest negative
regression coefficients, i.e., axitinib, erlotinib, RAPTA-C
and BEZ-235, inhibited ECRF24 viability most effectively
(Fig. 1d, green arrows). A regression model containing all
regression coefficients (i.e., a non-stepwise linear regres-
sion model) is provided in Supplementary Fig. S2B.
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In a parallel approach, we also investigated the best drug
combinations for ECRF24 migration inhibition. Even
though single drugs generally showed a stronger response
in the cell migration assay (Supplementary Fig. S2A), the
process of migration was less affected, reaching a max-
imum effect of 40 % inhibition in the given conditions
(Supplementary Fig. S3B). The optimization of EC mi-
gration inhibition was not further pursued. Yet, regression
analysis also revealed strong single-drug linear and
quadratic contributions for erlotinib, RAPTA-C and BEZ-
235.
Refined search leads to further optimized synergistic
drug combinations
Subsequently, a second FSC-based optimization was per-
formed with the above-selected compounds, i.e., axitinib
(3), erlotinib (4), RAPTA-C (8) and BEZ-235 (9), each
now considered at five drug doses with a maximum activity
of 25 % at the highest dose (Fig. 2a; single-drug effects in
Supplementary Fig. S3). The most effective combinations
resulting in more than 50 % inhibition of ECRF24 cell
viability identified in the second screen are provided in
Fig. 2a. The square icons represent the individual drug
combinations, where the color and pattern can be used to
identify the drug and its applied dosage. The strongest
synergistic activity [i.e., combination index (CI)\1] was
observed for combinations containing 4+8+9 (combina-
tions labeled I, II, IV, V, VI, Fig. 2a (remaining results in
Supplementary Fig. S4) or only 4+8 (labeled VIII). Two
of the effective combinations identified, III and VII,
showed antagonism (CI[ 1), and both contained axitinib
(3).
Linear regression modeling of data showed the single-
drug linear contributions of all compounds, as well as the
single-drug quadratic effect of 4, to be significant (Fig. 2b,
green arrows). Response surfaces (Fig. 2c) provide a visual
representation of the relationship between the system out-
put (EC viability) and the varying dose of only two drugs in
the combination. Interestingly, surfaces containing 3 (bot-
tom row) show that increasing the dose of 3 does not
enhance the combination efficacy (red). These response
surfaces show a relatively smooth response when doses of
the given drugs are varied. This “smoothness” indicates
that a moderate change in the dose of a single drug in the
range of the experimental conditions near the optimal
output investigated will most likely not result in a sig-
nificant change in the output response. This implies a
certain amount of “stability” in the optimal drug mixture
which may facilitate its translation to different models.
Table 2 Drug dose values used
for in vivo assays
Treatmentb Compoundsa % CTRL ± SEMc
3
(axitinib)
4
(erlotinib)
8
(RAPTA-C)
9
(BEZ-235)
CAM (µg/kg)
I 0 29 615 0.04 41 ± 9.0
II 0 29 307 0.04 51 ± 14
VI 0 2.9 307 0.04 32 ± 4.0
VII 18 29 230 0.02 13 ± 6.0
VIII 0 29 307 0 47 ± 14
Mice (mg/kg)
VI 0 15 40 10 24 ± 14
VIII 0 5 40 0 84 ± 16
41 0 5 0 0 102 ± 25
42 0 15 0 0 94 ± 34
4opt 0 50 0 0 29 ± 9.0
82 0 0 40 0 90 ± 17
8opt 0 0 100 0 58 ± 9.0
94 0 0 0 10 77 ± 12
9opt 0 0 0 30 33 ± 14
a Corresponding dose of each compound for single-drug and combination therapy. Compounds are rep-
resented as numbers 3, 4, 8 or 9, representing axitinib, erlotinib, RAPTA-C or BEZ-235, respectively. Drug
doses are provided in µg/kg for the CAM model and mg/kg in the mouse model
b Administered treatment, either a single drug represented by the drug number (3, 4, 8, 9) and the dosage
level indicated as a subscript, or drug combinations represented by the letters I–VIII
c The respective tumor growth inhibition efficacy represented as a percentage of the control (±SEM)
236 Angiogenesis (2015) 18:233–244
123
Selected optimized drug combinations exhibit
enhanced endothelial cell specificity
The optimized drug combinations I–VIII (Fig. 2a) and
corresponding single drugs were tested for viability of
different cell types and shown in comparison with ECRF24
(Fig. 3a; Supplementary Fig. S5). The activity in ECRF24
was confirmed in primary ECs (HUVEC, Fig. 3a) and was
much stronger than that of non-malignant cell types (adult
human dermal fibroblasts (HDFa), human peripheral blood
mononuclear cells (PBMCs) and tumor cells 786-O renal
cell adenocarcinoma, HT-29 colorectal carcinomas, A2780
ovarian adenocarcinoma, LS174T colorectal adenocarci-
noma and MDA-MB-231 breast adenocarcinoma),
indicating an enhanced EC specificity. Combinations I–
VIII only modestly affected cell motility in ECRF24 and
786-O cell lines in a wound-healing or scratch assay
(Fig. 3b). The effect of individual compounds and combi-
nations on ECRF24 apoptosis induction was assessed based
on the analysis of the DNA content by flow cytometry.
Several combinations (II, III, V, VI, VII) induced apop-
tosis in 20–30 % of ECRF24 cells (Fig. 3c).
Finally, the effect of combination VI on the inhibition of
tip cells was assessed both in vitro and in vivo. FACS
analysis shows a reduction in the number of CD34+ tip
cells [32, 38, 39] after treating HUVEC cultures in vitro
with VI. Quantification of these results is provided in the
bar graph as compared to single-drug treatments (Fig. 3d,
top left). Additionally, CD34+ tip cells treated with VI
present with a clearly different cellular organization of the
actin fibers stained with phalloidin, as compared to control
cells (Fig. 3d, top right), compatible with decreased mi-
gratory activity.
The inhibition of tip cells in vivo was shown in the
chicken chorioallantoic membrane (CAM) model follow-
ing vaso-occlusive Visudyne®-photodynamic therapy (V-
PDT) [33]. In the control treatment group, vascular sprouts
led by tip cells can be seen growing into the treated area
24 h after V-PDT treatment starting the revascularization
of the tissue (Fig. 3d, bottom left, green arrows). A sig-
nificant reduction in the number of sprouting tip cells can
be seen in the group treated with VI following V-PDT
(Fig. 3d, bottom right, red arrows).
Successful translation of optimal drug combinations
into in vivo cancer models
A2780 cells were transplanted onto the chorioallantoic
membrane of the chicken embryo and were allowed to
grow forming vascularized tumors. Tumors were treated
Fig. 1 Optimization of the inhibition of endothelial cell viability.
a Schematic diagram of the FSC technique loop (blue arrow loop) and
modeling (green arrow loop) used for in vitro drug optimization. FSC
starts with randomly selected drug combinations (yellow arrow) and
implements an algorithm-guided closed-loop feedback search to
iteratively optimize the results of an in vitro cell assay (blue arrows).
Once a plateau in the output is reached, the data obtained from the
optimization are used to model the system, analyze drug interactions
and eliminate certain drugs (green arrows). Using a refined set of
drugs, the drug combination is again optimized with FSC (blue
arrows). b Dose–response curve of sunitinib for cell viability
bioassay. c Output results (in vitro EC viability, represented as a
percentage of the control) for the 10 iterations of the FSC optimization
performed. Box plots provide median and interquartile ranges of the
cell response to the 19 best drug combinations identified by the end of
each iterative cycle of the FSC optimization.Dotted lines, representing
maximum and minimum (red) output values, showed no improvement
in the best-optimized combination over iterations 8–10. d Regression
coefficients obtained from the stepwise linear regression model
generated with the data obtained from the optimization described
above. The coefficient of determination (R2) is provided in the bottom
right of the graph. Green arrows indicate single-drug contributions
which significantly inhibit EC viability. * indicates p value\0.05 and
** indicates p value\0.01. (Color figure online)
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with combinations I, II, VI, VII and VIII by intravenous
injection on treatment days 1 and 2 (Fig. 4a, red arrows).
Doses (subsequently identified by a subscript) were trans-
lated to this model maintaining the drug dose ratios and
taking into account the single-drug efficacy in this model
(Fig. 4b; Table 2, Supplementary Methods). Drug combi-
nation VII (33+44+81+92) synergistically (CI 0.66)
inhibited tumor growth by 87 % (* p \ 0.03, Fig. 4a).
Based on results in Fig. 3a, this activity could be due to the
dual action on both ECRF24 and A2780 cells. Combination
VI (41+82+94) synergistically inhibited tumor growth by
68 % (Fig. 4a, c, **p\ 0.002, CI 0.34) through mainly
anti-angiogenic activity (compare Fig. 3a). Of note, none of
these doses inhibited tumor growth significantly when ap-
plied individually (Fig. 4b). As group VII experienced
weight loss (Fig. 4d, **p\0.004), it was not further exam-
ined. Microvessel density (MVD) assessment (Fig. 4e)
revealed that control tumors were well vascularized. MVD
Fig. 2 Identification of the optimal four-drug combinations for the
inhibition of ECRF24 viability. a Efficacy of the best combinations
identified to inhibit ECRF24 viability, using the concentrations of
each drug presented in the legend at the top right. Best-performing
combinations resulting in 50 % or more inhibition are shown, with
their corresponding combination index (CI) values calculated using
CompuSYN®, indicating synergistic (CI\ 1), additive (CI = 1) or
antagonistic (CI [ 1) interactions. The square icons present the
specific combinations, where each position in the square and color
corresponds to a specific drug [i.e., axitinib (3) in blue, erlotinib (4) in
red, RAPTA-C (8) in green and BEZ-235 (3) in yellow] and the
concentrations (in µM) of each compound are represented by the
different patterns. The most promising combinations, labeled I–VIII,
represent a mean of at least two independent experiments, with three
replications each, and error bars represent the SEM. b Regression
coefficients for the second-order linear regression model generated
based on the data from the optimization of the refined four-drug
combination. The green arrows indicate significant regression terms
that inhibit cell viability, while the red arrow indicates terms that
stimulates cell activity. c Response surfaces show the effect on the
system output of varying the concentration of two drugs, while
the concentration of the other two drugs remains fixed. Note the
smoothness of the curves, indicating that moderate changes in the
dosing of a single drug do not result in major output differences.
* indicates significance p value\0.05 and **p value\0.01. (Color
figure online)
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was 50–60 % lower in tumors treated with VI (**p\0.008)
and VIII (*p = 0.01, Fig. 4f). Based on these data, VI was
selected as the most promising combination.
Combinations VI and VIII were studied in athymic
mice grafted with human LS174T colorectal adenocarci-
noma. Drug doses were adapted to this model based on
single-drug tumor growth inhibition efficacy (Supplemen-
tary Methods). Mice were treated daily with vehicle
(CTRL), VI (42+82+94) and VIII (41+82) (Fig. 5a;
Table 2). VI and VIII inhibited tumor growth significantly
by 76 ± 14 % (**p\0.0001, CI 0.56) and 16 ± 16 % (CI
0.73), respectively (Fig. 5a). Drugs applied individually in-
hibited tumor growth onlymarginally, by 6% (42), 10% (82)
or 23 % (94) (*p\0.013, Fig. 5b). Interestingly, since the
LS174T cell line was not sensitive to VI (Fig. 3a), effective
tumor inhibition (Fig. 5a, c)was attributed to the inhibition of
angiogenesis.MVDassessment indicated thatVI suppressed
angiogenesis by approximately 80 % (**p\ 0.001), com-
pared with control tumors (Fig. 5d). No significant weight
loss was recorded in either of the combinations tested
(Fig. 5e). In contrast, individual compounds administered at
optimal monotherapy doses, capable of effective tumor
growth inhibition (Supplementary Fig. S6C) resulted in
considerable body weight loss.
Discussion
Next to the identification of novel targets as well as en-
dogenous and synthetic novel angiogenesis inhibitors [40,
41], the combination of therapies is globally seen as a
bFig. 3 Validation of the best drug combinations. The effects of the
most promising drug combinations (I–VIII from Fig. 2) were tested
on the viability of the following non-malignant and cancerous cell
lines: primary EC (HUVEC), adult human dermal fibroblasts (HDFa),
human peripheral blood mononuclear cells (PBMCs) and five human
tumor cell lines, i.e., A2780 ovarian adenocarcinoma, 786-O renal
cell carcinoma, MDA-MB-231 breast adenocarcinoma and LS174T
and HT-29 colorectal carcinomas (a) and on the migration of ECRF24
and 786-O cells (b). Images on the left show an example of migration
assay, where a scratch is made in a cell monolayer at t = 0 and the
relative closure of this scratch is measured after 7 h. c Effects of
individual compounds and combinations on ECRF24 apoptosis induc-
tion. Images show the analysis of the DNA content by flow cytometry,
after fixation of the cells in 70 % ethanol, a DNA extraction step and
staining with PI for cells in the control (CTRL) and combination VI
group. * indicates significance p value \0.05 and ** indicates
significance p value\0.01 with student’s t test. Values represent the
mean of at least two independent experiments with three replications
each, and error bars represent the SEM. d Combination therapy VI
inhibits tip cells in vitro and in vivo. FACS analysis show the decrease
in CD34+ cells VI treated in HUVEC cultures, which is quantified in
the bar graph and compared to single-drug treatments. CD34+ tip cells
treated with VI present with a clearly different cellular organization of
the actin fibers stained with phalloidin as compared to control cells,
compatible with decreased migratory activity. Bar stands for 25 μm.
The FITC-dextran fluorescence (FITC-dextran, 20 kDa, 20 μl, 25 mg/
ml, Sigma-Aldrich) angiographies below show the chicken chorioal-
lantoic membrane (CAM) capillary plexus at the edges of the
Visudyne®-photodynamic therapy (V-PDT; 5 J/cm2 and 35 mW/cm2
at 420 ± 20 nm)-treated zones 24 h post-V-PDT, where the tip cells
form the leading edge of the sprouting vasculature (green arrows). A
major lack of sprouting tip cells (red arrows) is visible after treatment
V-PDT with immediate of combination VI. (Color figure online)
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promising strategy to improve cancer therapy. The FSC
technique was used to navigate through the large para-
metric space of nine compounds, each considered at four
doses, aiming for an optimal angiostatic drug combination.
Using a simple in vitro endothelial cell (EC) viability
bioassay as the output, an optimal low-dose drug combi-
nations containing axitinib (3), erlotinib (4), RAPTA-C (8)
and BEZ-235 (9) was found. The most efficient of these
combinations was also effectively inhibiting cancer in two
in vivo animal models. We observed that (1) while some
drugs showed synergistic interactions, others showed ad-
ditive or even antagonistic behavior, (2) the observed
synergy was drug dose ratio dependent, (3) the combina-
tion of angiostatic drugs enhanced endothelial specificity,
(4) screening on EC migration did not identify highly ef-
ficient drug combinations, and (5) in vitro optimized anti-
angiogenic drug combinations translated to anti-angiogenic
anticancer effects in vivo.
We previously demonstrated that multi-drug effects can
be expressed by a quadratic relationship of the drug–drug
interactions [42], which was confirmed in bacterial systems
[43]. Here, we have further demonstrated that the response
surface for the whole range of drugs and drug doses applied
can be expressed as a second-order equation that can be
used to formulate optimal drug combinations. The results
of this regression modeling (Supplementary Methods)
permitted us to eliminate sunitinib (6) a compound which is
known to have a similar target profile as axitinib (3) (note
that both inhibit signaling of VEGF and PDGF [44]). The
exclusion of sunitinib over axitinib appears justifiable, as
axitinib is known to be a more selective TKI with stronger
affinity for the same targets [44]. Similarly, the exclusion
Fig. 4 Inhibition of A2780 tumor growth on the CAM by the optimal
drug combinations. Growth curves of A2780 tumors grafted on the
CAM (n = 10) showing tumor volume as a function of treatment day
for various drug combinations (a) and single-drug treatments (b). “S”
indicates synergy. Compounds were freshly premixed and adminis-
tered i.v. on treatment days 1 and 2 (red arrows in a). Data points
represent the average tumor volume as a percentage of the final
control volume per experiment. c Representative images of vehicle
(CTRL) and combination VI treated tumors. d Mean embryo body
weight on the last experiment day for selected treatment groups.
e Representative images of CD31-stained tumor sections are shown.
The bar in the lower right of the image represents 0.2 mm. The whole
image was linearly adjusted for brightness and contrast. fMicrovessel
density quantification measured as the number of vessels per mm2 and
represented as a percentage of the control (CTRL). * indicates p value
\0.05 and ** indicates p value\0.01 student’s t test. Error bars
represent the SEM. N = 3 for condition 41. N = 5–11 for all other
groups. (Color figure online)
240 Angiogenesis (2015) 18:233–244
123
of bevacizumab (2) was expected, as it is known that EC
does not use VEGF as an autocrine growth factor, and
tumor angiogenesis is mainly driven by tumor produced
VEGF [10].
The four drugs with significant inhibitory single-drug
linear contributions to cell viability were compounds axi-
tinib, erlotinib, RAPTA-C and BEZ-235 (Fig. 1d). In terms
of intracellular signaling, this combination of drugs appears
to make sense in retrospect. EGFR targeting by erlotinib
and VEGFR targeting by axitinib result in inhibition of two
largely synergistic and widely used cellular signaling
pathways, i.e., the PI3K/AKT/mTOR and the ras/raf/MEK/
MAPK signaling pathway, respectively. Since mTORC1
and mTORC2 belong to the PI3K/AKT pathway, one
would expect that both signaling pathways are inhibited by
EGFR and VEGFR inhibitors. It is also expected that a
drug that targets histone proteins, such as RAPTA-C [45],
can reinforce the angiostatic effect, as intervention with
histone–DNA interactions is known to be angiostatic from
the many reports on histone deacetylase inhibitors [46–48].
Fig. 5 Inhibition of LS174T tumor growth in athymic mice by the
optimal drug combinations. a LS174T tumors grafted subcutaneously
in athymic Swiss nu/nu mice and treated daily with the drug
combinations as listed in Table 2. b Inhibition of tumor growth by
single compounds at indicated doses. Data points represent the
average tumor volume as a percentage of the final CTRL volume per
experiment, and error bars represent the SEM; N = 3–9. *p\ 0.05
and **p\ 0.01 (two-way ANOVA). “S” indicates synergy (CI\ 1).
c Representative images of vehicle-treated (CTRL) and tumors
treated with drug combination VI on the last experiment day.
d Representative images of immunohistochemical staining for the EC
marker CD31 and corresponding quantification of microvessel
density, measured as the number of vessels per mm2 and presented
as a percentage of the CTRL. Results show significantly reduced
microvessel density in tumors treated with VI. The bar in the lower
panel image represents 0.2 mm and is valid for both images. The
whole images were linearly adjusted for brightness and contrast.
e Body weight change during the experiment. *p \ 0.05 and
**p\ 0.01 (student t test). 4 (erlotinib), 8 (RAPTA-C) and 9 (BEZ-
235). The error bars represent the SEM. (Color figure online)
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mTOR and EGFR inhibitors have already been identified
as a synergistic combination in various cancer cell types
[49, 50], despite clinically observed toxicity [51, 52].
Based on the analysis of the response surfaces of the
second-order linear regression model generated from the
four-drug optimization data (Fig. 2c) and embryo weight
loss observed in the CAM model (Fig. 4d), axitinib was
eliminated from further investigation. Thus, the optimal
drug combination containing erlotinib, RAPTA-C and
BEZ-235 was identified. It allowed for dose reductions of
5-, 11- and 6-fold, respectively, as compared to the
equivalent single-drug dose efficiencies in vitro. Interest-
ingly, enhanced EC specificity was observed for the
combinations when compared to the individual com-
pounds. This is another indication that the parallel blocking
of multiple angiogenesis pathways can result in synergism
for the angiostatic outcome. Simultaneous targeting of
different signaling pathways may limit the probability of
cells to develop acquired resistance [16].
The migration-based optimization screen failed to reach
effective combinations (Supplementary Fig. S3B). This
may suggest that proliferation is more dominant in the
process of angiogenesis than cell migration, which has also
been proposed by others [53]. The same may also be re-
flected by clinical trials, where proliferation inhibitors
(such as sunitinib and BEZ-235) were more successful than
migration inhibitors (the αvβ3 inhibitor cilengitide [54] and
the α5β1 antibody volociximab [55]). Another possible
explanation for enhanced success with the proliferation
assay over the migration assay may be the selective nature
of synergistic drug interactions. As seen by Lehar et al.
[15], drug combinations could attain greater selectivity.
They suggested that “synergistic combinations tend to be
more specific to particular cellular phenotypes than are
single drugs.” This may explain the preferred success of the
screen through selection on basis of proliferation, rather
than cell migration.
The optimal drug mixture inhibited tumor growth by
approximately 80 %, most likely by an inhibitory effect on
angiogenesis. Although the detailed mechanism of com-
bination therapy still needs to be understood, the induction
of apoptosis as well as the inhibition of tip cells shows part
of the effector mechanism. Targeting of tip cells may be
another attractive strategy as these cells are indispensable
for sprouting angiogenesis. The results provide a promising
option for future clinical anti-angiogenic applications.
One might expect that the differences in pharmacoki-
netics between the components of the drug mixture may
interfere with obtaining good results in vivo. Our results
imply that (1) the best drug combinations found show
smooth response surfaces (Fig. 2c, i.e., moderate changes
in drug ratios do not significantly change the output), (2)
response surfaces, giving a mathematical description of the
magnitude of the interaction for all drug pairs, confirmed
in vivo treatment outcome (compare Figs. 2c, 5a), and (3)
EC viability observed in vitro seems to be a relatively good
parameter for translation to vascular density reduction and
tumor growth inhibition in vivo.
The current study shows that FSC applied in vitro can be
used for the fast and reliable identification of potent, low-
dose angiostatic drug combinations in vivo. It is likely that
combining the optimal anti-angiogenic compounds with
other treatment strategies may lead to even better cancer
treatment outcomes. The capacity to normalize the tumor
vasculature provides angiostatic strategies with outstanding
combination therapy features [56, 57]. The impact of the
method also lies in the fact that it can be applied in a
variety of situations, e.g., for finding drug mixtures directly
targeting tumor cells. This strategy would then also offer
the opportunity for a personalized approach, by performing
a drug screen on freshly isolated tumor cells from a patient
biopsy. Such strategy would also depend on faster
screening methods. We are currently working on im-
provement of the FSC method in order to make the
selection procedure faster. In conclusion, designing effec-
tive, synergistic and specific multi-component drug
combinations may become a key approach in developing
new therapies for cancer and other diseases.
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